jun 18, 2021 - > Health Economic analysis 3 Per patient, 1 round Cytosponge test + endoscopy + treatment costed £82 more than usual care. For patients who will not develop BE, we gained: 1. additional 0.015 QALY 2. ICER of £5500 per QALY gained For patients who have BE dysplasia/ cancer, the cost-effective was over 90% at a willingness-to-pay threshold of £20000 per QALY. Conclusion: Cytosponge is cost-effective, this will increase with more patients accepting this test.
Added to timeline:
Date:
jun 18, 2021
Now
~ 4 years ago